Yungjin Pharm. Co., Ltd. (003520.KS) Stock
Yungjin Pharm. Co., Ltd.

Company profile
Yungjin Pharm. reported revenue of 254.26 billion KRW for fiscal year 2025, up 0.9% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 63.76 billion KRW, down 0.5% from a year before. In Q1 2026 it reported a net loss of 2.28 billion KRW, against net income of 976.29 million KRW a year earlier. Our analysis of its filings shows revenue growing from 234.90 billion KRW in fiscal year 2023 to 254.26 billion KRW in fiscal year 2025, 4.0% a year on average.
What stands out
- It reported a net loss of 227.66 million KRW in fiscal year 2025, after a profit of 1.23 billion KRW in fiscal year 2024.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Yungjin Pharm. Co., Ltd.
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
Largest shareholders
- Kt&G Corporation52.45%
Share of the company, as of September 25, 2026
Leadership
- Kisoo Lee — Chairman of the Board of Directors, President & CEO, 59
- ByeongHo Park — CFO & MD, 58
- UngYeol Yang — MD & GM of Sales HQ, 48
- Joongyoun Cho — MD & Global Headquarters GM, 46
- HongJun Park — Managing Director, 51
How much revenue does Yungjin Pharm. make?
Yungjin Pharm. reported 254.26 billion KRW in revenue for fiscal year 2025, up 0.9% from 252.04 billion KRW in fiscal year 2024. In Q1 2026 revenue was 63.76 billion KRW.
What companies are similar to Yungjin Pharm.?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ilsung Is Co., Ltd. (003120.KS), Samil Pharmaceutical Co.,Ltd (000520.KS), Hana Pharm Co., Ltd. (293480.KS), Dongwha Pharm.Co.,Ltd (000020.KS).
Has Yungjin Pharm. made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 11.58 billion KRW; FY2022, a loss of 21.96 billion KRW; FY2023, a loss of 3.88 billion KRW; FY2024, 1.23 billion KRW; FY2025, a loss of 227.66 million KRW. It reported a net loss in 4 of these 5 years.
How has Yungjin Pharm.'s revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 196.07 billion KRW; FY2022, 218.38 billion KRW; FY2023, 234.90 billion KRW; FY2024, 252.04 billion KRW; FY2025, 254.26 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Yungjin Pharm. Co., Ltd. (003520.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003520.KS